 <h1>Andexxa Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>coagulation factor Xa</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about coagulation factor Xa. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Andexxa.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to coagulation factor Xa: intravenous powder for solution</i></p><h3>Warning</h3><p class="blackboxWarning-title">Intravenous route (Powder for Solution)</p><p>Thromboembolic Risks, Ischemic Risks, Cardiac Arrest, and Sudden DeathsTreatment with coagulation factor Xa (recombinant) IV injection has been associated with serious and life-threatening adverse events, including:Arterial and venous thrombolic eventsIschemic events, including myocardial infarction and ischemic strokeCardiac arrestSudden deathsMonitor for thromboembolic events and initiate anticoagulation when medically appropriate. Monitor for symptoms and signs that precede cardiac arrest and provide treatment as needed.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, coagulation factor Xa (the active ingredient contained in Andexxa) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking coagulation factor Xa:</p><p>
<i>More common</i>
</p><ul>
<li>Anxiety</li>
<li>blue lips, fingernails, or skin</li>
<li>chest pain or discomfort</li>
<li>confusion</li>
<li>cool, sweaty skin</li>
<li>cough</li>
<li>decreased urine output</li>
<li>difficulty in speaking</li>
<li>dilated neck veins</li>
<li>dizziness</li>
<li>double vision</li>
<li>extreme tiredness or weakness</li>
<li>fainting</li>
<li>fast heartbeat</li>
<li>headache</li>
<li>inability to move the arms, legs, or facial muscles</li>
<li>inability to speak</li>
<li>irregular heartbeat</li>
<li>irregular, fast or slow, or shallow breathing</li>
<li>lightheadedness</li>
<li>nausea</li>
<li>pain or discomfort in the arms, jaw, back, or neck pain</li>
<li>redness, or swelling in the arm or leg</li>
<li>slow speech</li>
<li>sweating</li>
<li>swelling of the face, fingers, feet, or lower legs</li>
<li>tightness in the chest</li>
<li>troubled breathing</li>
<li>vomiting</li>
<li>weakness</li>
<li>weight gain</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Fast, pounding, or irregular heartbeat or pulse</li>
<li>palpitations</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of coagulation factor Xa may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Bladder pain</li>
<li>bloody or cloudy urine</li>
<li>change in taste</li>
<li>chills</li>
<li>cough</li>
<li>difficult, burning, or painful urination</li>
<li>feeling of warmth</li>
<li>fever</li>
<li>frequent urge to urinate</li>
<li>loss of taste</li>
<li>lower back or side pain</li>
<li>redness of the face, neck, arms, and occasionally, upper chest</li>
<li>sneezing</li>
<li>sore throat</li>
</ul><p>
<!-- end intravenous powder for solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to coagulation factor Xa: intravenous powder for injection</i></p><h3>General</h3><p>The most common adverse reactions (5% or greater) were urinary tract infections and pneumonia.<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Infusion-related reactions (18%), death prior to day 30 follow-up (14%)</p>
<p><b>Common</b> (1% to 10%): Sudden death</p>
<p><b>Frequency not reported</b>: Feeling hot<sup>[Ref]</sup></p><p>In the ongoing ANNEXA-4 study, there were 25 deaths (14%) prior to the day 30 follow-up visit.  The percentage of patients, by bleeding type, who died prior to the day 30 follow-up was: 14% for intracranial bleeding, 10% for gastrointestinal bleeding, and 19% for other bleeding types.<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Antibodies against this drug (up to 17%)<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Deep vein thrombosis, acute myocardial infarction, cardiogenic shock, congestive heart failure</p>
<p><b>Uncommon</b> (0.1% to 1%): Cardiac arrest, cardiac thrombus, iliac artery thrombosis, non-sustained ventricular tachycardia</p>
<p><b>Frequency not reported</b>: Flushing<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Pulmonary embolism, acute respiratory failure</p>
<p><b>Frequency not reported</b>: Cough, dyspnea, pneumonia<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Frequency not reported</b>: Urinary tract infection<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Frequency not reported</b>: Mild hives<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Ischemic stroke</p>
<p><b>Uncommon</b> (0.1% to 1%): Embolic stroke</p>
<p><b>Frequency not reported</b>: Dysgeusia<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Andexxa (coagulation factor Xa)." Portola Pharmaceuticals, South San Francisco, CA. </p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>What is the difference between Andexxa and Praxbind?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about Andexxa (coagulation factor Xa)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: anticoagulant reversal agents</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Andexxa &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Reversal of Anticoagulation</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to coagulation factor Xa: intravenous powder for injection</i></p><h3>General</h3><p>The most common adverse reactions (5% or greater) were urinary tract infections and pneumonia.<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Infusion-related reactions (18%), death prior to day 30 follow-up (14%)</p><p><b>Common</b> (1% to 10%): Sudden death</p><p><b>Frequency not reported</b>: Feeling hot<sup>[Ref]</sup></p><p>In the ongoing ANNEXA-4 study, there were 25 deaths (14%) prior to the day 30 follow-up visit.  The percentage of patients, by bleeding type, who died prior to the day 30 follow-up was: 14% for intracranial bleeding, 10% for gastrointestinal bleeding, and 19% for other bleeding types.<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Antibodies against this drug (up to 17%)<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Deep vein thrombosis, acute myocardial infarction, cardiogenic shock, congestive heart failure</p><p><b>Uncommon</b> (0.1% to 1%): Cardiac arrest, cardiac thrombus, iliac artery thrombosis, non-sustained ventricular tachycardia</p><p><b>Frequency not reported</b>: Flushing<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Pulmonary embolism, acute respiratory failure</p><p><b>Frequency not reported</b>: Cough, dyspnea, pneumonia<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Frequency not reported</b>: Urinary tract infection<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Frequency not reported</b>: Mild hives<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Ischemic stroke</p><p><b>Uncommon</b> (0.1% to 1%): Embolic stroke</p><p><b>Frequency not reported</b>: Dysgeusia<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Andexxa (coagulation factor Xa)." Portola Pharmaceuticals, South San Francisco, CA. </p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>What is the difference between Andexxa and Praxbind?</li>
</ul><h2>More about Andexxa (coagulation factor Xa)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: anticoagulant reversal agents</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Andexxa &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Reversal of Anticoagulation</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>